KURA vs SMMT
KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | KURA | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $10.45 | $14.98 | |
| Market cap as of 2026-07-25 | $914M | $10.6B | |
| PEG as of 2026-07-25 | -0.05 | -1.21 | SMMT lower |
| Net margin as of 2026-07-25 | -411.2% | -9027.1% | KURA higher |
| Gross margin as of 2026-07-25 | +99.9% | n/a | |
| Operating margin as of 2026-07-25 | -443.5% | -8108.3% | KURA higher |
| ROE as of 2026-07-25 | -141.9% | -291.2% | KURA higher |
| ROA as of 2026-07-25 | -43.3% | -243.1% | KURA higher |
| Debt / equity as of 2026-07-25 | 0.09 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-07-25 | +29.5% | n/a | |
| Beta as of 2026-07-25 | 0.37 | -1.34 | |
| 1-year return as of 2026-07-23 close | +60.6% | -46.5% | KURA higher |
Fundamentals: Finnhub, as of 2026-07-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.